JP2019146574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019146574A5 JP2019146574A5 JP2019071336A JP2019071336A JP2019146574A5 JP 2019146574 A5 JP2019146574 A5 JP 2019146574A5 JP 2019071336 A JP2019071336 A JP 2019071336A JP 2019071336 A JP2019071336 A JP 2019071336A JP 2019146574 A5 JP2019146574 A5 JP 2019146574A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- hiv
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15200138.4 | 2015-12-15 | ||
| EP15200138 | 2015-12-15 | ||
| EP16194124.0 | 2016-10-17 | ||
| EP16194124 | 2016-10-17 | ||
| JP2018531537A JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531537A Division JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019146574A JP2019146574A (ja) | 2019-09-05 |
| JP2019146574A5 true JP2019146574A5 (https=) | 2020-02-06 |
| JP6959289B2 JP6959289B2 (ja) | 2021-11-02 |
Family
ID=57737697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531537A Active JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
| JP2019071336A Expired - Fee Related JP6959289B2 (ja) | 2015-12-15 | 2019-04-03 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531537A Active JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10369214B2 (https=) |
| EP (3) | EP3584252B1 (https=) |
| JP (2) | JP6510149B2 (https=) |
| CN (2) | CN114686495A (https=) |
| AU (2) | AU2016369326B2 (https=) |
| BR (1) | BR112018011122A2 (https=) |
| CA (1) | CA3008542C (https=) |
| CY (2) | CY1122705T1 (https=) |
| DK (2) | DK3584252T3 (https=) |
| EA (1) | EA038974B1 (https=) |
| ES (2) | ES2898271T3 (https=) |
| HR (2) | HRP20211566T1 (https=) |
| HU (2) | HUE045993T2 (https=) |
| IL (1) | IL259942B2 (https=) |
| LT (2) | LT3390430T (https=) |
| MA (3) | MA47522B1 (https=) |
| MD (2) | MD3584252T2 (https=) |
| ME (1) | ME03545B (https=) |
| MX (2) | MX383507B (https=) |
| PH (1) | PH12018501047A1 (https=) |
| PL (2) | PL3584252T3 (https=) |
| PT (1) | PT3390430T (https=) |
| RS (2) | RS59447B1 (https=) |
| SG (2) | SG10202109457RA (https=) |
| SI (2) | SI3390430T1 (https=) |
| SM (2) | SMT202100623T1 (https=) |
| TW (2) | TWI707039B (https=) |
| WO (1) | WO2017102929A1 (https=) |
| ZA (1) | ZA201803978B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106999571B (zh) | 2014-09-26 | 2020-10-02 | 贝斯以色列护理医疗中心有限公司 | 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物 |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
| DK3584252T3 (da) | 2015-12-15 | 2021-11-15 | Janssen Vaccines & Prevention Bv | Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf |
| MA45381A (fr) | 2016-06-16 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Formulation de vaccin contre le vih |
| JP2019526580A (ja) | 2016-09-02 | 2019-09-19 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法 |
| PT3512543T (pt) | 2016-09-15 | 2020-10-13 | Janssen Vaccines & Prevention Bv | Trímero que estabiliza mutações das proteínas do envelope do hiv |
| KR20200015759A (ko) * | 2017-06-15 | 2020-02-12 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법 |
| AU2018304502B2 (en) | 2017-07-19 | 2022-03-31 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing HIV envelope protein mutations |
| US20190083620A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| KR20230019227A (ko) * | 2017-11-17 | 2023-02-07 | 그리폴스 다이어그노스틱 솔루션즈 인크. | 신규한 포유동물 발현 인간 면역결핍 바이러스 외피 단백질 항원 |
| CN114269363A (zh) * | 2019-04-17 | 2022-04-01 | 威斯达研究所 | 用于hiv疫苗应用的复制缺陷型腺病毒载体 |
| WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| CN114585639A (zh) | 2019-11-07 | 2022-06-03 | 扬森疫苗与预防公司 | 蛋白质纯化 |
| US20210353744A1 (en) | 2020-05-12 | 2021-11-18 | Janssen Vaccines Prevention B.V. | Administration of homologous adenoviral vectors |
| WO2021249011A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2022006095A2 (en) * | 2020-06-29 | 2022-01-06 | Duke University | Mosaic hiv-1 envelopes to induce adcc responses |
| WO2022084333A1 (en) | 2020-10-20 | 2022-04-28 | Janssen Vaccines & Prevention B.V. | Hiv vaccine regimens |
| JP2024509769A (ja) | 2021-02-23 | 2024-03-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 三量体安定化ｈｉｖエンベロープタンパク質変異 |
| US20230000973A1 (en) * | 2021-06-25 | 2023-01-05 | Janssen Vaccines & Prevention B.V. | Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment |
| WO2023242155A1 (en) | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions and methods for the diagnosis of hiv infection |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
| ES2372823T3 (es) | 1999-05-17 | 2012-01-26 | Crucell Holland B.V. | Adenovirus recombinante del serotipo ad11. |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| WO2003104467A1 (en) | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
| US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| EP1214333A4 (en) | 1999-09-17 | 2005-01-19 | Dana Farber Cancer Inst Inc | SOLUBLE STABILIZED GLYCOPROTEIN TRIMERS |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| EP2280074A3 (en) * | 2001-07-05 | 2011-06-22 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
| CA2785699A1 (en) * | 2001-07-05 | 2003-01-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| EP1497440B1 (en) | 2002-04-25 | 2008-08-20 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| JP2006509039A (ja) | 2002-12-03 | 2006-03-16 | ユニバーシティ オブ マサチューセッツ | 多価初代ｈｉｖ−１糖タンパク質ｄｎａワクチンおよびワクチン接種方法 |
| EP2363143A3 (en) | 2003-03-28 | 2012-02-15 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
| WO2005027840A2 (en) | 2003-09-15 | 2005-03-31 | Chiron Corporation | Combination approaches for generating immune responses |
| US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
| DE602005017743D1 (de) | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| AU2005243730B2 (en) * | 2004-04-12 | 2010-05-27 | Genvec, Inc. | Method of using adenoviral vectors to induce an immune response |
| EP1766097A4 (en) | 2004-06-15 | 2008-03-19 | Progenics Pharm Inc | HIV-1 NEUTRALIZING ANTIBODIES INDUCED BY A TRIMER HIV-1 HYLLGLYCOPROTEIN COMPLEX |
| AU2005274948B2 (en) * | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
| US9453239B2 (en) * | 2004-08-27 | 2016-09-27 | Emory University | Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes |
| AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
| CN101588813A (zh) * | 2005-04-12 | 2009-11-25 | 杜克大学 | 诱导人类免疫缺陷病毒的中和抗体的方法 |
| CA2656741A1 (en) | 2005-07-06 | 2007-01-11 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
| CN101969996A (zh) | 2005-08-23 | 2011-02-09 | 加利福尼亚大学董事会 | 多价疫苗 |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| EP2040747A4 (en) | 2006-06-19 | 2010-08-25 | Progenics Pharm Inc | SOLUBLE STABILIZED TRIMERS HIV CREAM PROTEINS AND ITS USE |
| US7939083B2 (en) | 2006-10-23 | 2011-05-10 | Progenics Pharmaceuticals Inc. | Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain |
| US20080279879A1 (en) | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
| PL2137210T3 (pl) | 2007-03-02 | 2017-06-30 | Glaxosmithkline Biologicals Sa | Nowy sposób i kompozycje |
| SMT202000101T1 (it) | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| NZ602504A (en) | 2008-11-18 | 2014-01-31 | Beth Israel Hospital | Antiviral vaccines with improved cellular immunogenicity |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| PL2391638T3 (pl) | 2009-02-02 | 2018-11-30 | Glaxosmithkline Biologicals Sa | Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| WO2011082087A2 (en) | 2010-01-04 | 2011-07-07 | Kj Biosciences, Llc | Dps fusion proteins for use in vaccines and diagnostics |
| CA2786333C (en) | 2010-01-28 | 2018-03-20 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of mva |
| PT3556396T (pt) | 2010-08-31 | 2022-07-04 | Scripps Research Inst | Anticorpos neutralizantes do vírus da imunodeficiência humana (vih) |
| DK2655604T3 (en) | 2010-12-14 | 2018-08-06 | Us Gov Health & Human Services | ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES |
| WO2012149038A1 (en) * | 2011-04-25 | 2012-11-01 | Advanced Bioscience Laboratories, Inc. | Truncated hiv envelope proteins (env), methods and compositions related thereto |
| WO2013036791A2 (en) | 2011-09-09 | 2013-03-14 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| WO2013040766A1 (zh) * | 2011-09-21 | 2013-03-28 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 可诱导针对hiv的广谱免疫应答的方法和疫苗 |
| WO2013055908A1 (en) | 2011-10-12 | 2013-04-18 | The Scripps Research Institute | An hiv-1 gp120 mini v3 loop and uses thereof |
| US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
| US10106781B2 (en) | 2012-11-16 | 2018-10-23 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
| SG10201705880QA (en) | 2013-01-07 | 2017-08-30 | Beth Israel Deaconess Medical Ct Inc | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| US10248758B2 (en) | 2013-02-07 | 2019-04-02 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| US9624510B2 (en) * | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
| WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| DK3052518T3 (da) * | 2013-10-04 | 2020-04-06 | Beth Israel Deaconess Medical Ct Inc | Stabiliserede humant immundefektvirus-(hiv)-klade c-kappe-(env)-trimer-vacciner og fremgangsmåder til anvendelse deraf |
| CA2941116A1 (en) * | 2014-02-28 | 2015-09-03 | Janssen Vaccines & Prevention B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| WO2016037154A1 (en) | 2014-09-04 | 2016-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant hiv-1 envelope proteins and their use |
| CN106999571B (zh) | 2014-09-26 | 2020-10-02 | 贝斯以色列护理医疗中心有限公司 | 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物 |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| DK3271729T3 (da) * | 2015-03-18 | 2020-12-14 | Janssen Vaccines & Prevention Bv | Analyser til rekombinante ekspressionssystemer |
| DK3584252T3 (da) | 2015-12-15 | 2021-11-15 | Janssen Vaccines & Prevention Bv | Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf |
| MA45381A (fr) | 2016-06-16 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Formulation de vaccin contre le vih |
| JP2019526580A (ja) | 2016-09-02 | 2019-09-19 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法 |
| PT3512543T (pt) | 2016-09-15 | 2020-10-13 | Janssen Vaccines & Prevention Bv | Trímero que estabiliza mutações das proteínas do envelope do hiv |
| DE102018124348A1 (de) | 2018-10-02 | 2020-04-02 | Haver & Boecker Ohg | Füllkasten und Verfahren zum Füllen von Gebinden |
-
2016
- 2016-12-15 DK DK19186284.6T patent/DK3584252T3/da active
- 2016-12-15 PL PL19186284T patent/PL3584252T3/pl unknown
- 2016-12-15 TW TW105141650A patent/TWI707039B/zh not_active IP Right Cessation
- 2016-12-15 MD MDE20200025T patent/MD3584252T2/ro not_active IP Right Cessation
- 2016-12-15 SG SG10202109457R patent/SG10202109457RA/en unknown
- 2016-12-15 CN CN202210312432.0A patent/CN114686495A/zh active Pending
- 2016-12-15 CN CN201680073839.5A patent/CN108368157B/zh active Active
- 2016-12-15 SG SG11201804411TA patent/SG11201804411TA/en unknown
- 2016-12-15 US US15/380,123 patent/US10369214B2/en active Active
- 2016-12-15 SM SM20210623T patent/SMT202100623T1/it unknown
- 2016-12-15 SI SI201630480T patent/SI3390430T1/sl unknown
- 2016-12-15 LT LT16822410T patent/LT3390430T/lt unknown
- 2016-12-15 MA MA47522A patent/MA47522B1/fr unknown
- 2016-12-15 SI SI201631333T patent/SI3584252T1/sl unknown
- 2016-12-15 TW TW109138473A patent/TWI792091B/zh not_active IP Right Cessation
- 2016-12-15 EP EP19186284.6A patent/EP3584252B1/en active Active
- 2016-12-15 HU HUE16822410A patent/HUE045993T2/hu unknown
- 2016-12-15 CA CA3008542A patent/CA3008542C/en active Active
- 2016-12-15 LT LTEP19186284.6T patent/LT3584252T/lt unknown
- 2016-12-15 PT PT168224103T patent/PT3390430T/pt unknown
- 2016-12-15 EP EP21185351.0A patent/EP3964569A1/en not_active Withdrawn
- 2016-12-15 IL IL259942A patent/IL259942B2/en unknown
- 2016-12-15 MX MX2018007198A patent/MX383507B/es unknown
- 2016-12-15 RS RSP20191399 patent/RS59447B1/sr unknown
- 2016-12-15 ES ES19186284T patent/ES2898271T3/es active Active
- 2016-12-15 MD MDE20181009T patent/MD3390430T2/ro not_active IP Right Cessation
- 2016-12-15 HR HRP20211566TT patent/HRP20211566T1/hr unknown
- 2016-12-15 BR BR112018011122-8A patent/BR112018011122A2/pt active Search and Examination
- 2016-12-15 EP EP16822410.3A patent/EP3390430B1/en active Active
- 2016-12-15 DK DK16822410T patent/DK3390430T3/da active
- 2016-12-15 PL PL16822410T patent/PL3390430T3/pl unknown
- 2016-12-15 MA MA055825A patent/MA55825A/fr unknown
- 2016-12-15 ME MEP-2019-304A patent/ME03545B/me unknown
- 2016-12-15 MA MA44059A patent/MA44059B1/fr unknown
- 2016-12-15 WO PCT/EP2016/081159 patent/WO2017102929A1/en not_active Ceased
- 2016-12-15 ES ES16822410T patent/ES2753854T3/es active Active
- 2016-12-15 JP JP2018531537A patent/JP6510149B2/ja active Active
- 2016-12-15 SM SM20190629T patent/SMT201900629T1/it unknown
- 2016-12-15 AU AU2016369326A patent/AU2016369326B2/en active Active
- 2016-12-15 HR HRP20191902TT patent/HRP20191902T1/hr unknown
- 2016-12-15 RS RS20211171A patent/RS62360B1/sr unknown
- 2016-12-15 EA EA201891415A patent/EA038974B1/ru unknown
- 2016-12-15 HU HUE19186284A patent/HUE055916T2/hu unknown
-
2018
- 2018-05-16 PH PH12018501047A patent/PH12018501047A1/en unknown
- 2018-06-13 MX MX2021006931A patent/MX2021006931A/es unknown
- 2018-06-14 ZA ZA2018/03978A patent/ZA201803978B/en unknown
-
2019
- 2019-04-03 JP JP2019071336A patent/JP6959289B2/ja not_active Expired - Fee Related
- 2019-05-17 AU AU2019203468A patent/AU2019203468B2/en not_active Ceased
- 2019-06-13 US US16/440,463 patent/US10973907B2/en active Active
- 2019-11-13 CY CY20191101197T patent/CY1122705T1/el unknown
-
2021
- 2021-03-03 US US17/190,569 patent/US11896663B2/en active Active
- 2021-10-19 CY CY20211100901T patent/CY1125387T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019146574A5 (https=) | ||
| HRP20211566T1 (hr) | Antigeni, vektori, pripravci virusa humane imunodeficijencije i postupci njihove uporabe | |
| Kinney et al. | Nucleotide sequence of the 26 S mRNA of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and deduced sequence of the encoded structural proteins | |
| JP6306514B2 (ja) | Ｈｉｖワクチン接種のための免疫原 | |
| CN110958887B (zh) | 编码hiv抗原的痘病毒载体及其使用方法 | |
| CN1325512C (zh) | Hiv调节/辅助蛋白的融合蛋白 | |
| KR20120083899A (ko) | 마이코박테리아 백신들 | |
| JP2019527055A5 (https=) | ||
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| RU2015155821A (ru) | Вакцины против малярии | |
| JP2006523224A5 (https=) | ||
| JP2017531693A5 (https=) | ||
| JP2019214579A5 (https=) | ||
| KR20200100745A (ko) | B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물 | |
| ZA200504021B (en) | Methods and compositions for immunization against HIV | |
| EP3972642A1 (en) | Dosage regimens for vaccines | |
| JP6612237B2 (ja) | ヒトｔリンパ向性ウイルス１型に対する免疫応答を生成するためのレンチウイルスベクター | |
| Hara et al. | Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors | |
| Bongard et al. | Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors | |
| Bayer et al. | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes | |
| Chen et al. | Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses | |
| WO2023092023A2 (en) | Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19) | |
| Podschwadt et al. | A detailed analysis of F-MuLV-and SFFV-infected cells in Friend virus-infected mice reveals the contribution of both F-MuLV-and SFFV-infected cells to the interleukin-10 host response | |
| Huisman et al. | Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats | |
| Clade | Comparison of Human and Rhesus |